Additionally, some recent studies indicated that the methylation of the TRAIL-R4 promoter indeed predisposes to tumor formation, relapse and overall poor prognosis (van Noesel et al., 2002; Shivapurkar et al., 2004; Yang et al., 2007; Bonazzi et al., 2011; Lau et al., 2012; Ratzinger et al., 2014). Here, TNFRSF10D is linked to neoplasm.